Trial Profile
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Decitabine
- Indications Myelodysplastic syndromes; Myeloid leukaemia
- Focus Therapeutic Use
- Acronyms HOVON 135 AML /SAKK 30/15
- 21 Jun 2020 Results (n=144) from arm A and arm B of this trial assessing safety and overall survival presented at the 25th Congress of the European Haematology Association
- 12 Apr 2016 New trial record